Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.

导出 LinkOut

翻译打印收藏纠错

作者： Ersin,Özaslan ^[1] ; Halit,Karaca ; Sinan,Koca ; Alper,Sevinç ; Bekir,Hacioğlu ; Metin,Özkan ; Melike,Özçelik ; Ayşe O,Duran ; İlhan,Hacibekiroğlu ; Yaşar,Yildiz ; Özgür,Tanriverdi ; Serkan,Menekşe ; Asude,Aksoy ; Oktay,Bozkurt ; Semiha,Urvay ; Mükremin,Uysal ; Hacer,Demir ; Aydin,Çiltaş ; Faysal,Dane

作者单位： aDivision of Medical Oncology, Erciyes University School of Medicine, Kayseri bDivision of Medical Oncology, Marmara University School of Medicine cDivision of Medical Oncology, Kartal Training and Research Hospital, İstanbul dDivision of Medical Oncology, Gaziantep University School of Medicine, Gaziantep eDivision of Medical Oncology, Trakya University School of Medicine, Edirne fDivision of Medical Oncology, Abdurrahman Yurtaslan Training and Research Hospital gDivision of Medical Oncology, Gazi University School of Medicine, Ankara hDivision of Medical Oncology, İzmir Katip Çelebi University School of Medicine, İzmir iDivision of Medical Oncology, Muğla Sitki Koçman University School of Medicine, Muğla jDivision of Medical Oncology, Celal Bayar University School of Medicine, Manisa kDivision of Medical Oncology, Firat University School of Medicine, Elaziğ lDivision of Medical Oncology, Cumhuriyet University School of Medicine, Sivas mDivision of Medical Oncology, Afyon Kocatepe University School of Medicine, Afyon, Turkey. ^[1]